EDWARDS LIFESCIENCES CORP (EW) Fundamental Analysis & Valuation

NYSE:EW • US28176E1082

84.26 USD
+2.62 (+3.21%)
At close: Mar 9, 2026
84.26 USD
0 (0%)
After Hours: 3/9/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This EW fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

EW gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making EW a very profitable company, without any liquidiy or solvency issues. EW has a decent growth rate and is not valued too expensively. This makes EW very considerable for quality investing!


Dividend Valuation Growth Profitability Health

8

1. EW Profitability Analysis

1.1 Basic Checks

  • In the past year EW was profitable.
  • EW had a positive operating cash flow in the past year.
  • In the past 5 years EW has always been profitable.
  • In the past 5 years EW always reported a positive cash flow from operatings.
EW Yearly Net Income VS EBIT VS OCF VS FCFEW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

1.2 Ratios

  • The Return On Assets of EW (7.84%) is better than 88.59% of its industry peers.
  • EW's Return On Equity of 10.38% is amongst the best of the industry. EW outperforms 84.78% of its industry peers.
  • EW has a better Return On Invested Capital (12.01%) than 92.39% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for EW is above the industry average of 9.15%.
Industry RankSector Rank
ROA 7.84%
ROE 10.38%
ROIC 12.01%
ROA(3y)18.26%
ROA(5y)18.16%
ROE(3y)24.41%
ROE(5y)25.04%
ROIC(3y)13.04%
ROIC(5y)15.54%
EW Yearly ROA, ROE, ROICEW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • The Profit Margin of EW (17.69%) is better than 92.93% of its industry peers.
  • In the last couple of years the Profit Margin of EW has remained more or less at the same level.
  • EW has a Operating Margin of 27.17%. This is amongst the best in the industry. EW outperforms 95.65% of its industry peers.
  • In the last couple of years the Operating Margin of EW has declined.
  • EW has a Gross Margin of 78.01%. This is amongst the best in the industry. EW outperforms 90.22% of its industry peers.
  • EW's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27.17%
PM (TTM) 17.69%
GM 78.01%
OM growth 3Y-8.34%
OM growth 5Y-1.77%
PM growth 3Y-19.64%
PM growth 5Y-1.18%
GM growth 3Y-2.35%
GM growth 5Y0.69%
EW Yearly Profit, Operating, Gross MarginsEW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. EW Health Analysis

2.1 Basic Checks

  • EW has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for EW has been reduced compared to 1 year ago.
  • EW has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, EW has an improved debt to assets ratio.
EW Yearly Shares OutstandingEW Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
EW Yearly Total Debt VS Total AssetsEW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • EW has an Altman-Z score of 11.19. This indicates that EW is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of EW (11.19) is better than 92.39% of its industry peers.
  • The Debt to FCF ratio of EW is 0.45, which is an excellent value as it means it would take EW, only 0.45 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of EW (0.45) is better than 90.76% of its industry peers.
  • EW has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.06, EW is doing good in the industry, outperforming 67.93% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.45
Altman-Z 11.19
ROIC/WACC1.22
WACC9.87%
EW Yearly LT Debt VS Equity VS FCFEW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 3.72 indicates that EW has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 3.72, EW is doing good in the industry, outperforming 63.04% of the companies in the same industry.
  • A Quick Ratio of 3.09 indicates that EW has no problem at all paying its short term obligations.
  • EW's Quick ratio of 3.09 is fine compared to the rest of the industry. EW outperforms 66.30% of its industry peers.
Industry RankSector Rank
Current Ratio 3.72
Quick Ratio 3.09
EW Yearly Current Assets VS Current LiabilitesEW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. EW Growth Analysis

3.1 Past

  • EW shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.29%.
  • EW shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.67% yearly.
  • Looking at the last year, EW shows a quite strong growth in Revenue. The Revenue has grown by 10.86% in the last year.
  • EW shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.70% yearly.
EPS 1Y (TTM)-2.29%
EPS 3Y1.06%
EPS 5Y6.67%
EPS Q2Q%-1.69%
Revenue 1Y (TTM)10.86%
Revenue growth 3Y10.77%
Revenue growth 5Y6.7%
Sales Q2Q%13.26%

3.2 Future

  • EW is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.79% yearly.
  • Based on estimates for the next years, EW will show a quite strong growth in Revenue. The Revenue will grow by 9.72% on average per year.
EPS Next Y16.14%
EPS Next 2Y13.34%
EPS Next 3Y13.01%
EPS Next 5Y12.79%
Revenue Next Year10.47%
Revenue Next 2Y10.14%
Revenue Next 3Y10.12%
Revenue Next 5Y9.72%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EW Yearly Revenue VS EstimatesEW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B 8B
EW Yearly EPS VS EstimatesEW Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. EW Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 32.91, the valuation of EW can be described as expensive.
  • EW's Price/Earnings ratio is a bit cheaper when compared to the industry. EW is cheaper than 72.83% of the companies in the same industry.
  • EW is valuated rather expensively when we compare the Price/Earnings ratio to 26.46, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 28.34, EW can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, EW is valued a bit cheaper than the industry average as 73.37% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 24.65. EW is around the same levels.
Industry RankSector Rank
PE 32.91
Fwd PE 28.34
EW Price Earnings VS Forward Price EarningsEW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EW indicates a somewhat cheap valuation: EW is cheaper than 72.28% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, EW is valued a bit cheaper than the industry average as 75.54% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 36.63
EV/EBITDA 23.52
EW Per share dataEW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates EW does not grow enough to justify the current Price/Earnings ratio.
  • EW has an outstanding profitability rating, which may justify a higher PE ratio.
  • EW's earnings are expected to grow with 13.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.04
PEG (5Y)4.93
EPS Next 2Y13.34%
EPS Next 3Y13.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EW Dividend Analysis

5.1 Amount

  • EW does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EW Fundamentals: All Metrics, Ratios and Statistics

EDWARDS LIFESCIENCES CORP

NYSE:EW (3/9/2026, 8:04:00 PM)

After market: 84.26 0 (0%)

84.26

+2.62 (+3.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)04-21
Inst Owners89.94%
Inst Owner Change1.03%
Ins Owners0.11%
Ins Owner Change-1.9%
Market Cap48.90B
Revenue(TTM)6.07B
Net Income(TTM)1.07B
Analysts79.53
Price Target97.45 (15.65%)
Short Float %1.38%
Short Ratio1.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.39%
Min EPS beat(2)-8.84%
Max EPS beat(2)9.63%
EPS beat(4)3
Avg EPS beat(4)2.32%
Min EPS beat(4)-8.84%
Max EPS beat(4)9.63%
EPS beat(8)5
Avg EPS beat(8)1.48%
EPS beat(12)5
Avg EPS beat(12)0.35%
EPS beat(16)7
Avg EPS beat(16)-0.13%
Revenue beat(2)1
Avg Revenue beat(2)-0.31%
Min Revenue beat(2)-1.47%
Max Revenue beat(2)0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)0.85%
Revenue beat(8)1
Avg Revenue beat(8)-2.84%
Revenue beat(12)2
Avg Revenue beat(12)-2.11%
Revenue beat(16)2
Avg Revenue beat(16)-2.28%
PT rev (1m)-0.57%
PT rev (3m)1.7%
EPS NQ rev (1m)5.73%
EPS NQ rev (3m)6.23%
EPS NY rev (1m)0%
EPS NY rev (3m)1.11%
Revenue NQ rev (1m)1.79%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)0.67%
Revenue NY rev (3m)0.67%
Valuation
Industry RankSector Rank
PE 32.91
Fwd PE 28.34
P/S 8.06
P/FCF 36.63
P/OCF 30.65
P/B 4.73
P/tB 6.57
EV/EBITDA 23.52
EPS(TTM)2.56
EY3.04%
EPS(NY)2.97
Fwd EY3.53%
FCF(TTM)2.3
FCFY2.73%
OCF(TTM)2.75
OCFY3.26%
SpS10.46
BVpS17.81
TBVpS12.82
PEG (NY)2.04
PEG (5Y)4.93
Graham Number32.03
Profitability
Industry RankSector Rank
ROA 7.84%
ROE 10.38%
ROCE 13.87%
ROIC 12.01%
ROICexc 18.64%
ROICexgc 29.98%
OM 27.17%
PM (TTM) 17.69%
GM 78.01%
FCFM 22%
ROA(3y)18.26%
ROA(5y)18.16%
ROE(3y)24.41%
ROE(5y)25.04%
ROIC(3y)13.04%
ROIC(5y)15.54%
ROICexc(3y)18.54%
ROICexc(5y)20.56%
ROICexgc(3y)28.25%
ROICexgc(5y)29.44%
ROCE(3y)15.07%
ROCE(5y)17.95%
ROICexgc growth 3Y0.42%
ROICexgc growth 5Y-1.8%
ROICexc growth 3Y-6.11%
ROICexc growth 5Y-3.98%
OM growth 3Y-8.34%
OM growth 5Y-1.77%
PM growth 3Y-19.64%
PM growth 5Y-1.18%
GM growth 3Y-2.35%
GM growth 5Y0.69%
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.45
Debt/EBITDA 0.33
Cap/Depr 166.16%
Cap/Sales 4.29%
Interest Coverage 81.62
Cash Conversion 88.36%
Profit Quality 124.36%
Current Ratio 3.72
Quick Ratio 3.09
Altman-Z 11.19
F-Score6
WACC9.87%
ROIC/WACC1.22
Cap/Depr(3y)177.3%
Cap/Depr(5y)193.25%
Cap/Sales(3y)4.93%
Cap/Sales(5y)5.41%
Profit Quality(3y)58.49%
Profit Quality(5y)66.28%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.29%
EPS 3Y1.06%
EPS 5Y6.67%
EPS Q2Q%-1.69%
EPS Next Y16.14%
EPS Next 2Y13.34%
EPS Next 3Y13.01%
EPS Next 5Y12.79%
Revenue 1Y (TTM)10.86%
Revenue growth 3Y10.77%
Revenue growth 5Y6.7%
Sales Q2Q%13.26%
Revenue Next Year10.47%
Revenue Next 2Y10.14%
Revenue Next 3Y10.12%
Revenue Next 5Y9.72%
EBIT growth 1Y11.04%
EBIT growth 3Y1.54%
EBIT growth 5Y4.82%
EBIT Next Year25.88%
EBIT Next 3Y16.1%
EBIT Next 5Y14.72%
FCF growth 1Y413.66%
FCF growth 3Y11.88%
FCF growth 5Y15.59%
OCF growth 1Y194.16%
OCF growth 3Y9.4%
OCF growth 5Y8.64%

EDWARDS LIFESCIENCES CORP / EW FAQ

What is the fundamental rating for EW stock?

ChartMill assigns a fundamental rating of 7 / 10 to EW.


What is the valuation status for EW stock?

ChartMill assigns a valuation rating of 4 / 10 to EDWARDS LIFESCIENCES CORP (EW). This can be considered as Fairly Valued.


How profitable is EDWARDS LIFESCIENCES CORP (EW) stock?

EDWARDS LIFESCIENCES CORP (EW) has a profitability rating of 8 / 10.


What is the earnings growth outlook for EDWARDS LIFESCIENCES CORP?

The Earnings per Share (EPS) of EDWARDS LIFESCIENCES CORP (EW) is expected to grow by 16.14% in the next year.